Collaborative Arrangements and Licensing Agreements, Otsuka (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) PerformanceObligation	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) PerformanceObligation	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue	$ 225,250	$ 188,411	$ 344,748	$ 318,935
Otsuka [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront payment received	20,000
Maximum amount of payments receivable over term of collaboration	290,000		290,000
Maximum amount of upfront payments over term of collaboration	85,000		85,000
Maximum amount of regulatory milestone payments over term of collaboration	65,000		65,000
Maximum amount of sales milestone payments over term of collaboration	140,000		140,000
Cumulative payments received	$ 85,000		$ 85,000
Number of separate performance obligations | PerformanceObligation	2		2
Transaction price	$ 20,000		$ 20,000
Revenue	18,905	$ 0	19,691	$ 0
Deferred contract revenue	$ 8,800		$ 8,800		$ 8,500
Otsuka [Member] | Revenue [Member] | Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage	8.00%	0.00%	6.00%	0.00%
Otsuka [Member] | Maximum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Royalty percentage received on net sales of medicine			30.00%
Otsuka [Member] | Donidalorsen [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Next payment to be achieved	$ 15,000		$ 15,000
Otsuka [Member] | License of Donidalorsen [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Transaction price	17,500		17,500
Revenue	17,500
Otsuka [Member] | R&D Services for Donidalorsen [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Transaction price	$ 2,500		$ 2,500